GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xiangxue Pharmaceutical Co Ltd (SZSE:300147) » Definitions » Capex-to-Revenue

Xiangxue Pharmaceutical Co (SZSE:300147) Capex-to-Revenue : 0.01 (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Xiangxue Pharmaceutical Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Xiangxue Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-5.16 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥421.00 Mil.

Hence, Xiangxue Pharmaceutical Co's Capex-to-Revenue for the three months ended in Mar. 2025 was 0.01.


Xiangxue Pharmaceutical Co Capex-to-Revenue Historical Data

The historical data trend for Xiangxue Pharmaceutical Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xiangxue Pharmaceutical Co Capex-to-Revenue Chart

Xiangxue Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.17 0.17 0.02 0.02

Xiangxue Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.01 0.01 0.02 0.01

Competitive Comparison of Xiangxue Pharmaceutical Co's Capex-to-Revenue

For the Biotechnology subindustry, Xiangxue Pharmaceutical Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xiangxue Pharmaceutical Co's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xiangxue Pharmaceutical Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Xiangxue Pharmaceutical Co's Capex-to-Revenue falls into.


;
;

Xiangxue Pharmaceutical Co Capex-to-Revenue Calculation

Xiangxue Pharmaceutical Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-35.242) / 1858.662
=0.02

Xiangxue Pharmaceutical Co's Capex-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-5.156) / 421.004
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xiangxue Pharmaceutical Co  (SZSE:300147) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Xiangxue Pharmaceutical Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Xiangxue Pharmaceutical Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Xiangxue Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No 2 Jinfeng Road , Science City, Guangzhou Economic and Technological Development Z, Guangzhou, CHN, 510663
Xiangxue Pharmaceutical Co Ltd is a China-based company engages in the manufacture and distribution of pharmaceutical products. Its diversified healthcare portfolio includes Chinese Herbal Slices, TCM, Life Science, Biomedical Engineering health solutions (food and beverage), healthcare supplements and so on.
Executives
Huang Wei Hua Supervisors
Tan Wen Hui Director
Kang Zhi Ying Executives
Ceng Lun Executives
Liu Yan Executives
Lu Feng Executives
Xu Li Secretary, Director
Mo Zi Yu Supervisors
Mai Zhen Jiang Supervisors
Wang Yong Hui Directors, executives
He Tao Executives
Fang Wei Min Supervisors
Huang Bin Directors, Directors, and Executives
Wu Jun Executives
Chen Wen Jin Executives

Xiangxue Pharmaceutical Co Headlines

No Headlines